Syntheses of Antifungal Aureobasidin A Analogs with Alkyl Chains for Structure-activity Relationship

The syntheses of aureobasidin A (AbA) derivatives with alkyl chains and their in vitro structure-biological activity relationships are discussed. The analogs replaced at positions 6, 7, or 8 of AbA with either L-glutamic acid, δ-hydroxy-L-norvaline, or δ-hydroxy-N-methyl-L-norvaline are prepared. Th...

Full description

Saved in:
Bibliographic Details
Published inJournal of antibiotics Vol. 51; no. 3; pp. 359 - 367
Main Authors KUROME, TORU, INOUE, TETSUYA, TAKESAKO, KAZUTOH, KATO, IKUNOSHIN, INAMI, KAORU, SHIBA, TETSUO
Format Journal Article
LanguageEnglish
Published TOKYO JAPAN ANTIBIOTICS RESEARCH ASSOCIATION 01.03.1998
JAPAN ANTIBIOT RES ASSN
Japan Antibiotics Research Association
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The syntheses of aureobasidin A (AbA) derivatives with alkyl chains and their in vitro structure-biological activity relationships are discussed. The analogs replaced at positions 6, 7, or 8 of AbA with either L-glutamic acid, δ-hydroxy-L-norvaline, or δ-hydroxy-N-methyl-L-norvaline are prepared. The γ-carboxyl or δ-hydroxyl group of these new amino acids was coupled with acids, alcohols, or amines with alkyl chains. While the analogs having L-glutamic acid residue at positions 6 or 8 showed weak activity, esterification of the γ-carboxyl group with benzyl or shorter alkyl (C4 or C6) alcohols, significantly enhanced the activities. Introduction of longer alkyl (C14) chain to the same amino acids residues at positions 6, 7, or 8 resulted in total loss of antifungal activity. Among the lipophilic analogs in [L-Glu6] derivatives, the C6 alcohol ester showed the strongest antifungal activity against Candida spp. so far tested. None of the derivatives showed activity against Cryptococcus neoformans.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0021-8820
1881-1469
DOI:10.7164/antibiotics.51.359